- Home
- MESO vs STUB Comparison
MESO vs STUB Comparison
Compare MESO & STUB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MESO | STUB |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 2005 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MESO | STUB |
|---|---|---|
| Price | $16.39 | $6.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $18.15 |
| AVG Volume (30 Days) | 180.2K | ★ 7.2M |
| Earning Date | 02-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $1,745,188,000.00 |
| Revenue This Year | $629.74 | $19.18 |
| Revenue Next Year | $30.65 | $19.13 |
| P/E Ratio | ★ N/A | $110.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.05 | $5.74 |
| 52 Week High | $21.50 | $21.49 |
Technical Indicators
Market Signals| Indicator | MESO | STUB |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 30.85 |
| Support Level | $15.37 | $5.74 |
| Resistance Level | $17.10 | $10.51 |
| Average True Range (ATR) | 0.44 | 0.30 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 1.06 | 4.98 |
Price Performance
Historical ComparisonAbout MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
About STUB StubHub Holdings Inc.
Stubhub Holdings Inc operates a ticketing marketplace for live events where fans can buy tickets from sellers of all types through its StubHub and viagogo websites and mobile applications. The company generates majority of its revenue from United States.